Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP486937.RAacGMQzGYNxgzPC2RQY8DUB-rCNv6e2MNC_8BLOUFrYA130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP486937.RAacGMQzGYNxgzPC2RQY8DUB-rCNv6e2MNC_8BLOUFrYA130_assertion type Assertion NP486937.RAacGMQzGYNxgzPC2RQY8DUB-rCNv6e2MNC_8BLOUFrYA130_head.
- NP486937.RAacGMQzGYNxgzPC2RQY8DUB-rCNv6e2MNC_8BLOUFrYA130_assertion description "[Moreover, treatment of WT mice with soluble ObR fusion protein (ObR:Fc) increased the percentage of T(Regs) and ameliorated the clinical course and progression of disease in proteolipid protein peptide (PLP(139-151))-induced relapsing-experimental autoimmune encephalomyelitis (R-EAE), an animal model of RRMS.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP486937.RAacGMQzGYNxgzPC2RQY8DUB-rCNv6e2MNC_8BLOUFrYA130_provenance.
- NP486937.RAacGMQzGYNxgzPC2RQY8DUB-rCNv6e2MNC_8BLOUFrYA130_assertion evidence source_evidence_literature NP486937.RAacGMQzGYNxgzPC2RQY8DUB-rCNv6e2MNC_8BLOUFrYA130_provenance.
- NP486937.RAacGMQzGYNxgzPC2RQY8DUB-rCNv6e2MNC_8BLOUFrYA130_assertion SIO_000772 15788534 NP486937.RAacGMQzGYNxgzPC2RQY8DUB-rCNv6e2MNC_8BLOUFrYA130_provenance.
- NP486937.RAacGMQzGYNxgzPC2RQY8DUB-rCNv6e2MNC_8BLOUFrYA130_assertion wasDerivedFrom befree-2016 NP486937.RAacGMQzGYNxgzPC2RQY8DUB-rCNv6e2MNC_8BLOUFrYA130_provenance.
- NP486937.RAacGMQzGYNxgzPC2RQY8DUB-rCNv6e2MNC_8BLOUFrYA130_assertion wasGeneratedBy ECO_0000203 NP486937.RAacGMQzGYNxgzPC2RQY8DUB-rCNv6e2MNC_8BLOUFrYA130_provenance.